Barbara A. Parker

Barbara A. Parker

Auto-generated profile, based on publicly available information

Barbara A. Parker

UC San Diego Moores Cancer Center, UC San Diego , La Jolla, CA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2015 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
LCLisa Cadmus-Bertram
Lisa Cadmus-Bertram
BMBess H Marcus
Bess H Marcus
RPRuth E Patterson
Ruth E Patterson
BPBarbara A Parker
Barbara A Parker
BMBrittany L Morey
Brittany L Morey
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.

1 June 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
NVNeelima Vidula
Neelima Vidula
TRThereasa A. Rich
Thereasa A. Rich
OSOliver Sartor
Oliver Sartor
JYJennifer Yen
Jennifer Yen
AHAaron Hardin
Aaron Hardin
MCMassimo Cristofanilli
Massimo Cristofanilli
Purpose: Poly ADP-ribose inhibitors (PARPi) are efficacious in multiple cancers harboring germline (and possibly somatic) BRCA1/2 mutations. Acquired reversions can restore BRCA1/2 function, causing resistance to PARPi and/or platinum-based chemotherapy. The optimal method of identifying patients with germline, somatic, and/or reversion mutations in BRCA1/2 has not been established. Next-generation sequencing (NGS) of cell-free DNA (cfDNA) provides a platform to identify these three types of BRCA1/2 mutations. Methods: Patients with advanced breast, ovarian, prostate, or pancreatic cancer were tested using a clinically validated 73-gene cfDNA assay which evaluates single nucleotide variants and insertion-deletion mutations (indels) in BRCA1/2, and distinguishes somatic/reversion from germline mutations with high accuracy. Results: Among 828 patients, greater than or equal to 1 deleterious BRCA1/2 mutation was detected in 60 (7.2%) patients, including germline (n=42) and somatic (n=18) mutations. Common co-existing mutations included TP53 (61.6%), MYC (30%), PIK3CA (26.6%), BRAF (15%) and ESR1 (11.5%). Polyclonal reversion mutations (median, 5) were detected in 9/42 (21.4%) germline BRCA1/2 mutant patients, the majority (77.7%) of whom had prior PARPi exposure (median duration, 10 months). Serial cfDNA demonstrated emergence of reversion BRCA mutations under therapeutic pressure from initial PARPi exposure which contributed to subsequent resistance to PARPi and platinum therapy. Conclusions: cfDNA NGS identified high rates of therapeutically relevant mutations without foreknowledge of germline or tissue-based testing, including deleterious somatic BRCA1/2 mutations missed by germline testing and reversion mutations that can have important treatment implications. Further research is needed to confirm clinical application of these findings to guide precision medicine approaches for advanced malignancies.

16 September 2021 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
LELaura Esserman
Laura Esserman
MEMartin Eklund
Martin Eklund
LVLaura Van’t Veer
Laura Van’t Veer
YSYiwey Shieh
Yiwey Shieh
JTJeffrey Tice
Jeffrey Tice
MPMichael Plaza
Michael Plaza

25 October 2019 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
KHKamrul Hasan
Kamrul Hasan
GWGeorge F. Widhopf
George F. Widhopf
SZSuping Zhang
Suping Zhang
SLSharon M. Lam
Sharon M. Lam
ZSZhouxin Shen
Zhouxin Shen
TKThomas Kipps
Thomas Kipps
ROR1 is a conserved oncoembryonic surface protein expressed in breast cancer. Here we report that ROR1 associates with cortactin in primary breast-cancer cells or in MCF7 transfected to express ROR1. Wnt5a also induced ROR1-dependent tyrosine phosphorylation of cortactin (Y421), which recruited ARHGEF1 to activate RhoA and promote breast-cancer-cell migration; such effects could be inhibited by cirmtuzumab, a humanized mAb specific for ROR1. Furthermore, treatment of mice bearing breast-cancer xenograft with cirmtuzumab inhibited cortactin phosphorylation in vivo and impaired metastatic development. We established that the proline at 841 of ROR1 was required for it to recruit cortactin and ARHGEF1, activate RhoA, and enhance breast-cancer-cell migration in vitro or development of metastases in vivo. Collectively, these studies demonstrate that the interaction of ROR1 with cortactin plays an important role in breast-cancer-cell migration and metastasis.

11 October 2019 in JMIR Cancer
Verified
Journal Article
Open access
SHSheri J Hartman
Sheri J Hartman
LWLauren S Weiner
Lauren S Weiner
SNSandahl H Nelson
Sandahl H Nelson
LNLoki Natarajan
Loki Natarajan
RPRuth E Patterson
Ruth E Patterson
Dorothy D SearsDorothy D Sears
Dorothy D Sears
Background: Emerging research suggests that increasing physical activity can help improve cognition among breast cancer survivors. However, little is known about the mechanism through which physical activity impacts cancer survivors’ cognition.Objective: The objective of this secondary analysis examined physical and psychological function potentially linking physical activity with changes in cognition among breast cancer survivors in a randomized controlled trial where the exercise arm had greater improvements in cognition than the control arm.Methods: A total of 87 sedentary breast cancer survivors were randomized to a 12-week physical activity intervention (n=43) or control condition (n=44). Objectively measured processing speed (National Institutes of Health Toolbox Oral Symbol Digit), self-reported cognition (patient-reported outcomes measurement information system [PROMIS] cognitive abilities), PROMIS measures of physical and psychological function (depression, anxiety, fatigue, and physical functioning), and plasma biomarkers (brain-derived neurotrophic factor, homeostatic model assessment 2 of insulin resistance, and C-reactive protein [CRP]) were collected at baseline and 12 weeks. Linear mixed-effects models tested intervention effects on changes in physical and psychological function variables and biomarkers. Bootstrapping was used to assess mediation. Exploratory analyses examined self-reported cognitive abilities and processing speed as mediators of the intervention effect on physical functioning.Results: Participants in the exercise arm had significantly greater improvements in physical functioning (beta=1.23; 95% CI 2.42 to 0.03; P=.049) and reductions in anxiety (beta=−1.50; 95% CI −0.07 to −2.94; P=.04) than those in the control arm. Anxiety significantly mediated the intervention effect on cognitive abilities (bootstrap 95% CI −1.96 to −0.06), whereas physical functioning did not (bootstrap 95% CI −1.12 to 0.10). Neither anxiety (bootstrap 95% CI −1.18 to 0.74) nor physical functioning (bootstrap 95% CI −2.34 to 0.15) mediated the intervention effect on processing speed. Of the biomarkers, only CRP had greater changes in the exercise arm than the control arm (beta=.253; 95% CI −0.04 to 0.57; P=.09), but CRP was not associated with cognition; therefore, none of the biomarker measures mediated the intervention effect on cognition. Neither cognitive abilities (bootstrap 95% CI −0.06 to 0.68) nor processing speed (bootstrap 95% CI −0.15 to 0.63) mediated the intervention effect on physical function.Conclusions: Physical activity interventions may improve self-reported cognition by decreasing anxiety. If supported by larger studies, reducing anxiety may be an important target for improving self-reported cognition among cancer survivors.Trial Registration: ClinicalTrials.gov NCT02332876; https://clinicaltrials.gov/ct2/show/NCT02332876

6 January 2025 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ASAkshat Singhal
Akshat Singhal
XZXiaoyu Zhao
Xiaoyu Zhao
PWPatrick Wall
Patrick Wall
ESEmily So
Emily So
GCGuido Calderini
Guido Calderini
TITrey Ideker
Trey Ideker
The rapid evolution of machine learning has led to a proliferation of sophisticated models for predicting therapeutic responses in cancer. While many of these show promise in research, standards for clinical evaluation and adoption are lacking. Here, we propose seven hallmarks by which predictive oncology models can be assessed and compared. These are Data Relevance and Actionability, Expressive Architecture, Standardized Benchmarking, Generalizability, Interpretability, Accessibility and Reproducibility, and Fairness. Considerations for each hallmark are discussed along with an example model scorecard. We encourage the broader community, including researchers, clinicians, and regulators, to engage in shaping these guidelines toward a concise set of standards. Significance: As the field of artificial intelligence evolves rapidly, these hallmarks are intended to capture fundamental, complementary concepts necessary for the progress and timely adoption of predictive modeling in precision oncology. Through these hallmarks, we hope to establish standards and guidelines that enable the symbiotic development of artificial intelligence and precision oncology.